Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Editor
New York, USA
24+ years of experience
Scrip
By Jessica Merrill 14 Nov 2022
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
Scrip
By Jessica Merrill 20 Apr 2021
J&J employs 3,000 more people today than it did before US corporate tax reform in 2017, CFO Wolk said, highlighting the company's US investments.
Scrip
By Jessica Merrill 27 Nov 2020
Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.
Topic BioPharmaceutical
Scrip
By Jessica Merrill 19 Oct 2020
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.
Scrip
By Jessica Merrill 12 Mar 2020
Amid a stock market freefall spurred largely by coronavirus uncertainty, big pharma sought to reassure investors and the public that supply disruptions are not an immediate concern and they are monitoring business operations day-by-day.
Topic Coronavirus
Scrip
By Jessica Merrill 14 Aug 2019
Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.
Scrip
By Jessica Merrill 05 Aug 2019
Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.
Scrip
By Jessica Merrill 02 Jul 2019
The billionaire philanthropist and industry agitator took the stage at the Forbes Healthcare Summit to discuss why his foundation is focused on fixing drug pricing and supporting organizations like ICER and Patients for Affordable Drugs.
Scrip
By Jessica Merrill 02 Jul 2019
CEO Craig Wheeler talked toScripabout the challenging biosimilar market dynamics and the company's decision to end most biosimilar drug development. The path to value creation in biosimilars is not clear, he said.
Scrip
By Jessica Merrill 02 Jul 2019
PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads.
Topic Approvals Drug Review
Scrip
By Jessica Merrill 28 May 2019
J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly.
Topic Policy & Regulation
Scrip
By Jessica Merrill 28 May 2019
After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.
Topic Policy & Regulation
Scrip
By Jessica Merrill 28 May 2019
Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.
Topic Business Strategies
Scrip
By Jessica Merrill 16 Jan 2019
Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.
Scrip
By Jessica Merrill 22 Aug 2018
The fast-growing oncology business represented 29% of AstraZeneca's second quarter sales, fueled by 44% revenue growth, outpacing sales of respiratory drugs and narrowing the gap with CV/metabolic.
Topic Cancer
Medtech Insight
22 Jul 2022
Scrip
21 Jul 2022
Scrip
11 Jul 2022
Scrip
07 Jul 2022
Scrip
05 Jul 2022
Scrip
23 Jun 2022
Scrip
21 Jun 2022
Scrip
14 Jun 2022
Scrip
13 Jun 2022
Scrip
06 Jun 2022
Scrip
01 Jun 2022
Scrip
31 May 2022
In Vivo
23 May 2022
Scrip
19 May 2022
Scrip
16 May 2022
